Johnson & Johnson $JNJ Stake Lifted by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 71.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 52,947 shares of the company’s stock after acquiring an additional 22,136 shares during the period. First Citizens Bank & Trust Co.’s holdings in Johnson & Johnson were worth $14,017,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. Auto Owners Insurance Co lifted its stake in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $1,967,399,000. Diamant Asset Management Inc. increased its holdings in Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after acquiring an additional 4,454,778 shares during the last quarter. Corient Private Wealth LP lifted its holdings in Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after purchasing an additional 3,393,981 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported adjusted third-quarter EPS of $2.59, above the $2.53 analyst consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine led growth, including strong oncology demand and a 68% increase in TREMFYA sales to approximately $2.4 billion. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Management raised its 2026 outlook to adjusted EPS of $11.05–$11.15 and revenue of $101.0–$101.4 billion. The guidance midpoint is broadly in line with current analyst expectations and signals continued confidence in pharmaceutical growth. Johnson & Johnson raises 2026 guidance as quarterly sales climb
• Positive Sentiment: The board declared a quarterly dividend of $1.34 per share, or $5.36 annualized, supporting JNJ’s income-investment appeal. Johnson & Johnson announces quarterly dividend
• Neutral Sentiment: Johnson & Johnson is leaning toward spinning off its hips-and-knees orthopedics business. The move could sharpen the company’s focus and unlock value, but execution details and timing remain uncertain. J&J is leaning toward spinning out its hips-and-knees business
• Negative Sentiment: MedTech grew operationally by only about 2.5% and missed expectations, with weakness in Surgery and Cardiovascular markets outside the United States. Middle East-related budget pressure also weighed on medical-device sales, raising concerns about the segment’s near-term growth.
• Negative Sentiment: Reported net income fell sharply to $210 million, or $0.09 per share, because of special charges tied primarily to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. These charges overshadowed the adjusted earnings beat. Johnson & Johnson falls after quarterly report despite higher outlook
• Negative Sentiment: Erste Group Bank lowered its FY2027 EPS estimate to $12.65 from $12.83, reflecting concerns about future costs from business-development activity and ongoing operational headwinds. Johnson & Johnson analyst estimate update

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research report on Monday, August 3rd. Morgan Stanley increased their target price on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Weiss Ratings raised Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $276.22.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 5.6%

Shares of JNJ stock opened at $248.90 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a market capitalization of $599.83 billion, a PE ratio of 28.84, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The business’s fifty day moving average is $265.89 and its 200 day moving average is $249.37.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the company earned $2.80 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.09 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.